Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.63 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29015227 | 0.88 | MCHR1 (0.48) | MCHR1XDHDHFRDCPSCYP2D6 | |
| SCHEMBL2728360 | 0.83 | MCHR1 (0.50) | MCHR1DHFRDCPS | |
| SCHEMBL3415459 | 0.80 | MCHR1 (0.50) | MCHR1XDHDHFRDCPSTLR7 | |
| SCHEMBL5883858 | 0.78 | MCHR1 (1.00) | MCHR1DHFRDCPS | |
| SCHEMBL5343908 | 0.75 | MCHR1 (0.41) | MCHR1DHFRDCPSFFAR2CYP2D6 | |
| SCHEMBL2143997 | 0.75 | MCHR1 (0.50) | MCHR1DHFRDCPS | |
| SCHEMBL5343605 | 0.74 | ALOX5AP (0.45) | FFAR2CYP2D6 | |
| SCHEMBL24265468 | 0.74 | CYP2D6 (0.53) | MCHR1DHFRDCPSCYP2D6TLR7 | |
| SCHEMBL3100924 | 0.74 | CYP2D6 (0.47) | MCHR1DHFRDCPSCYP2D6GRM4 | |
| SCHEMBL31118706 | 0.71 | DHFR (0.41) | MCHR1DHFRDCPSFFAR2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | MCHR1 4295/4885XDH 32/4885DHFR 569/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | MCHR1 4295/4885XDH 32/4885DHFR 569/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | MCHR1 4295/4885XDH 32/4885DHFR 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.